Overactive bladder (OAB) is relatively common in the general population but more common in women, especially in postmenopausal women with the genitourinary syndrome of menopause (GSM).
AIM OF THE WORK:
The aim of this study was to assess the efficacy of local estrogen hormone in improving the OAB symptoms in postmenopausal women with GSM.
PATIENTS AND METHODS:
A randomized, double-blind, placebo-controlled was carried out on 56 patients with GSM with the complaints consistent with OAB and recruited from the urogynecology out-patient clinic, Department of obstetrics and gynecology at El Shatby Alexandria University Hospital. Patients were divided into two groups: Group (A) received 0.5 g of conjugated estrogen (Premarin vaginal cream) twice weekly for 8 weeks, and group (B) received a placebo at the same dose. All subjects were subjected to full history taking, questionnaire derived from the UDI-6 and IIQ-7, clinical examination and investigations including complete urine analysis and urodynamic studies. After 8 weeks, patients in both groups were assessed again by a UDI-6 and IIQ-7 and urodynamics, and the results of both groups were compared.